SCHEMBL23217344

SCHEMBL23217344

COc1ccc(Cl)c(Cl)c1C1=C[C@@H](C(=O)O)N(C(=O)O)C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 5/20 0.35
FFAR2 O15552 2/20 0.34
DRD2 P14416 1/20 0.33
HTR2A P28223 4/20 0.33
HTR2B P41595 4/20 0.33
CLCN2 P51788 1/20 0.33
NPSR1 Q6W5P4 2/20 0.32
S1PR1 P21453 2/20 0.32
KDM4E B2RXH2 1/20 0.32
S1PR4 O95977 1/20 0.32
HSP90AA1 P07900 1/20 0.32
MAPT P10636 1/20 0.32
G6PD P11413 1/20 0.32
MAPK1 P28482 1/20 0.32
OPRK1 P41145 1/20 0.32
HTT P42858 1/20 0.32
RAB9A P51151 1/20 0.32
CACNA1B Q00975 1/20 0.32
APBA1 Q02410 1/20 0.32
MCL1 Q07820 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23227234 0.77 CCNT1 (0.40) DRD2ALDH1A1CCNT1CDK9
SCHEMBL23217738 0.73 FFAR2 (0.38) HTR2CFFAR2DRD2MCL1
SCHEMBL23214614 0.71 FFAR2 (0.35) HTR2CFFAR2DRD2HTR2AHTR2B
SCHEMBL23214510 0.71 FFAR2 (0.35) HTR2CFFAR2DRD2HTR2AHTR2B
SCHEMBL29219312 0.67 KDM4E (0.44) HTR2CHTR2AHTR2BNPSR1S1PR1
SCHEMBL23217480 0.67 HTR2C (0.44) HTR2CFFAR2DRD2HTR2AHTR2B
SCHEMBL23217172 0.67 HTR2C (0.44) HTR2CFFAR2DRD2HTR2AHTR2B
SCHEMBL23217560 0.65 HTR2A (0.42) HTR2CFFAR2DRD2HTR2AHTR2B
SCHEMBL23216594 0.65 AGTR2 (0.37) FFAR2DRD2ALDH1A1
SCHEMBL30120802 0.65 FFAR2 (0.47) HTR2CFFAR2HTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-02-16 US disclosed
EP-4041405-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. Shaw Research, LLC (US) 2022-08-17 EP disclosed
CN-114828963-A Arylheterobicyclic compounds as Kv1.3 potassium SHAKER channel blockers D·E·萧尔研究有限责任公司 2022-07-29 CN disclosed
WO-2021071832-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNB1, KCNJ2, KCNB2 HTR2C 1162/4885FFAR2 3024/4885DRD2 1975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.